title: [Local antitumor treatments].
abstract: The idea of intraoperative adjuvant treatment is not new. This review describes only the strategies studied in phase III clinical trials. Among these strategies, only Gliadel® obtained marketing authorization. Some immunotoxins, administered by convection-enhanced delivery, and a gene therapy approach using an adenovirus went through a phase II trial and are currently being studied in a phase III trial. Brachytherapy has never been validated by a clinical trial.
authors.affiliation: Département de neurochirurgie, CHU d'Angers, 4, rue Larrey, 49940 Angers cedex 9, France. phmenei@chu-angers.fr
authors.forename: P
authors.initials: P
authors.lastname: Menei
authors.forename: P
authors.initials: P
authors.lastname: Metellus
mesh_terms: D001672:Biocompatible Materials; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000628:therapy; D002330:Carmustine; D017326:Clinical Trials, Phase III as Topic; D003652:Decanoic Acids; D005909:Glioblastoma / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D011091:Polyesters
chemical_list: D001672:Biocompatible Materials; D003652:Decanoic Acids; D011091:Polyesters; C055401:decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; D002330:Carmustine